Skip to main content
OpenTrials
Completed

NCT Number: NCT02994875

Functional Magnetic Resonance Imaging of N-acetylcysteine in Cocaine Dependence

The objective of this research is to identify the functional neural mechanisms (as assessed using fMRI) of short-term N-acetylcysteine (NAC) administration among methadone-maintained individuals with cocaine dependence.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

Yale University School of Medicine

New Haven, Connecticut, 06519, United States

About this study

The objective of this research is to identify the functional neural mechanisms (as assessed using fMRI) of short-term N-acetylcysteine (NAC) administration among methadone-maintained individuals with cocaine dependence. Specifically, this application proposes to conduct a randomized, double-blind, placebo-controlled, cross-over pilot study to examine the effects of 7-day NAC administration (2400mg/day) on the neural networks engaged during response inhibition (Go/No-Go task) and affective (emotion-regulation task) processes among cocaine-dependent, methadone-maintained individuals (n=40; 20 per treatment-order condition).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • enrollment in the APT methadone program and maintained on a stable dose of methadone for ≥ 2 weeks
  • males or females, aged 18-65
  • confirmed DSM-IV diagnosis of current cocaine use disorder as assessed at the screening assessment
  • for women of a child-bearing age, acceptable birth control method
  • ability to commit to 4 weeks of study participation plus 1-month follow-up
  • willingness to be randomized to NAC or placebo
  • eligibility for MRI scanning and willingness to participate in MRI scanning.

Exclusion criteria

  • Do not meet DSM-IV criteria for cocaine-use disorder.
  • Meet DSM-IV psychiatric classifications for lifetime schizophrenia or bipolar disorder, or exhibit significant current suicidal or homicidal plans and intent such that hospitalization is required.
  • Meet DSM-IV criteria for current alcohol or other substance-use disorder dependence (with the exceptions of nicotine, cocaine and opioids).
  • Have previously taken or currently take NAC.
  • Have asthma (due to possible complications with NAC).
  • Cannot commit to 4-weeks of study participation or are unwilling to accept randomization.
  • Have any contraindications for MRI scanning (e.g., pregnancy, color-blindness, claustrophobia, metal implants that could interfere with MRI, any other contraindication to scanning).
  • Have lab work (complete blood count, urinalysis, liver function tests, thyroid function tests) suggesting the presence of any abnormalities or have a significant or unstable medical illness.
  • Are women who are pregnant or of a child-bearing age who do not agree to adequate contraception to prevent pregnancy during the study period.
  • Are not fluent in English.
  • Do not have at least a 6th grade reading level.
  • Cannot provide written, informed consent.

Treatment and study plan

N-acetylcysteine

Dietary Supplement

NAC is an FDA-approved dietary supplement with antioxidant properties that is available over-the-counter. NAC has no contraindications.

Other names: NAC

Placebo

Other

Sugar pill

Primary outcomes

  1. Change in neural network engagement measured using functional magnetic resonance imaging

    Time frame: 4 weeks

    The primary outcome measure for this study is change (NAC versus placebo) in neural network engagement during fMRI task performance.

Sponsors and collaborators

Lead sponsor

Yale University

Other

Collaborators

  • National Institute on Drug Abuse (NIDA)

Registry information

Important dates

Study start
2016
Primary completion
2020
Study completion
2020
First posted
Dec 16, 2016
Registry last updated
Oct 5, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.